Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
40 participants
OBSERVATIONAL
2014-03-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We aim to characterize oesophageal circumferential and longitudinal muscle contractility and LOS distensibility in patients with achalasia (either before or after treatment). This may allow an understanding of the mechanisms underlying persistent dysphagia and delayed oesophageal emptying after treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mechanisms of Weight Loss in Patients Diagnosed With Achalasia
NCT03063463
A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia
NCT00188344
Laparoscopic Dor Versus Toupet Fundoplication for the Treatment of Idiopathic Esophageal Achalasia
NCT00490750
Evaluation of the Effectiveness of Endoscopic "Rendez-vous" Technique Foresophageal Reconstructions for the Treatment of a Total and Extensive Disruption of the Esophagus
NCT02166957
The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation
NCT00164021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
On arrival at the GI physiology unit, patients will be given verbal and written information about the study (including standard care and non-standard tests). They will then be asked if they wish to participate. Informed written consent will be obtained.
Participants will complete questionnaires and HRM. If HRM is not consistent with achalasia, the patient's participation in the study ends. If HRM is consistent with achalasia then the participant will then undergo EndoFLIP, HFIUS and TBO.
Assessments are as follows (but are not necessarily done in the order given:
A. Perception of dysphagia (using MAYO and Eckardt questionnaires)
Dysphagia questionnaires are a non-intrusive, quick and well validated method of assessing the perception of dysphagia and are considered part of standard care.
B. Oesophageal circular muscle function (using HRM)
HRM is part of standard care and is performed in the GI physiology unit routinely by appropriately trained and experienced investigators. It involves the insertion of a small catheter into the oesophagus via the transnasal route. The only risk to the patient is nasopharyngeal discomfort on insertion, which is reduced by the use of nasal lignocaine spray. Ten 5ml water swallows are assessed and the duration is typically 10 to 15 minutes.
C. Oesophageal emptying (using TBO)
TBO is a standard/routine investigation in assessing suspected or treated achalasia. It is a variant of a "barium swallow". The patient drinks 200mls of barium and has plain radiological films taken at 1,3 and 5 minutes. The TBO is performed in the GI physiology unit by investigators with appropriate training and certification (IRMER). It involves the use of ionising radiation (X rays) but is not an experimental procedure.
D. Distensibility of the mid oesophagus and LOS (using EndoFLIP)
Endoscopic functional luminal imaging probe (EndoFLIP) is not part of standard care. It is very similar to HRM as it uses a small catheter which is inserted into the oesophagus via the transnasal route. There is a small water filled balloon at the tip of the catheter which is gently inflated using water. The distensibility of any part of the oesophagus is thus able to be measured. Like HRM the only risk to the participant is nasopharyngeal discomfort on insertion. The duration of the procedure is 10 to 15 minutes.
E. Longitudinal muscle thickness and contraction (using HFIUS)
High frequency intra luminal ultrasound (HFIUS) is not part of standard care and will be performed in the endoscopy unit of the Royal London Hospital (which is located very close to the GI physiology unit). Like HRM and EndoFLIP, it uses a small catheter which is inserted into the oesophagus via the transnasal route. It is able to visualise the layers of the oesophageal wall. Again, the only risk to the patient is discomfort. The procedure takes about 10 to 15 minutes.
Patients with achalasia will classified on TBO as having either normal or delayed oesophageal emptying. The perception of dysphagia and motility characteristics of these two groups will then be compared using an independent samples t test. SPSS will be used for statistical analysis. An independent statistician has reviewed and approved the protocol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written ICF signed voluntarily before the first trial-related activity.
* Male or female, aged 18-70
* If the subject is a woman of childbearing potential, she must have a negative urine pregnancy test before the start of assessments
Exclusion Criteria
* History of gastrointestinal tract surgery, fundoplication, endoscopic anti reflux procedure or any other recent abdominal operation in the last 6 months
* Major psychiatric, neurological, respiratory, liver, haemorrhagic and cardiac disorders, malignancies
* Pregnancy
* Subjects with a documented history of long segment (\>3 cm) Barrett's oesophagus, large (\> 3 cm) hiatus hernia, structural abnormalities of oesophagus (i.e. Rings, webs, scleroderma)
* Use of prokinetic medication less than 7 days before the start of the study
* Any condition that in the opinion of the Investigator would complicate or compromise the trial or the well-being of the subject.
* Evidence of any clinically relevant pathology that could interfere with trial results or put subject safety at risk.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Barts & The London NHS Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barts Health NHS Trust
London, UK, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
009393
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.